TARGET: SORAFENIB IN THE ELDERLY
≥ 70 years
(n = 70)
< 70 years
(n = 381)
PFS (months)
6.1
6.0
Clinical benefit rate*
84 3%
83 5%
.
.
Time‐to‐health status
Deterioration (days)
121
90
*Clinical Benefit Rate = CR + PR + SD ≥ 12 weeks
Tumor assessments by computed tomography or magnetic resonance imaging of the chest, abdomen, and pelvis were performed before treatment, on day 1 of cycle two,
and at every cycle thereafter until the end of treatment. Tumor response was assessed by RECIST
Eisen T, et al. J Natl Cancer Inst 2008;100:1454‐63
